Myasthaenia Gravis
2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
Cartesian TherapeuticsDecartes-08
argenxefgartigimod administration
Clinical Trials (2)
Total enrollment: 30 patients across 2 trials
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Start: May 2025Est. completion: Sep 2027
Phase 3Recruiting
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Start: Feb 2025Est. completion: Jan 202730 patients
Phase 3Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 30 patients
2 companies competing in this space